CDH1 and breast cancer: Moreover, the young onset of malignant breast neoplasia associated with a genetic susceptibility led the American Society of Breast Surgeons (ASCO), the Society of Surgical Oncology (SSO) and the NCCN breast cancer risk-reduction Guidelines to regard bilateral risk-reducing mastectomy as a reasonable option for women with deleterious mutations in BRCA1, BRCA2, CDH1, TP53, PALB2, STK11 or PTEN [8,15].